<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68711">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211326</url>
  </required_header>
  <id_info>
    <org_study_id>XY3-WARF1405A01</org_study_id>
    <secondary_id>ChiCTR-TRC-14004757</secondary_id>
    <nct_id>NCT02211326</nct_id>
  </id_info>
  <brief_title>Genotype-guided Warfarin Individualized Treatment</brief_title>
  <official_title>Pharmacogenetic Algorithm of Response to Warfarin During Initial Anticoagulation in Chinese Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the international pharmacogenetic
      algorithm is better than the standard initiation dosing and whether the two algorithms are
      suitable for Chinese elderly patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study protocol is a multicenter, randomized, patient-blinded and controlled trial,
      comparing two approaches among 864 enrolled AF(atrial fibrillation) or DVT(deep venous
      thrombosis) patients for guiding warfarin initial anticoagulation in Chinese elderly
      patients: the intervention group using the algorithm of International Warfarin
      Pharmacogenetic Consortium and its dose revision, and the control group using a standard
      initiation dose (2.25 mg).The study hypothesis is that the intervention group relative to
      the control group will increase the percentage of time in therapeutic INR (international
      normalized ratio) range during the first 3 months.This trial is the first prospective
      large-scale randomized controlled trial for elders in China. It is of great significance for
      promoting special crowd individualization of anticoagulants at home and abroad.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time in therapeutic INR range</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of time out of INR therapeutic range</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of warfarin dose adjustments</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">864</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Deep Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Genotype-guided dosing algorithm for warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard initiation dose for warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Genotype-guided dosing algorithm for warfarin</intervention_name>
    <description>Initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.</description>
    <arm_group_label>Genotype-guided dosing algorithm for warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard initiation dose for warfarin</intervention_name>
    <description>Initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.</description>
    <arm_group_label>Standard initiation dose for warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 60 years old.

          -  Require warfarin therapy for at least 12 weeks.

          -  Diagnosed with AF or DVT and target INR 1.5-2.5.

          -  Willingness and ability to sign informed consent.

          -  Can communicate effectively and complete the trial.

        Exclusion Criteria:

          -  Current treatment with any coumarin.

          -  Have known stable dose.

          -  Have known CYP2C9 or VKORC1 genotype.

          -  Expect to accept other treatment or other kinds of anticoagulant drugs.

          -  Contraindications to warfarin.

          -  Severe cognitive impairment which would have affected adherence to therapy as judged
             by the attending physician.

          -  Baseline INR≥1.5

          -  Alcoholism and substance abuse for past 12 months.

          -  Blood transfusion and bone marrow transplantation for past two weeks.

          -  Severe hepatic and renal dysfunction.

          -  History of major bleeding or bleeding disorder or higher risk of blood coagulation.

          -  History of positive hepatitis B antigen or hepatitis C antibody before Randomly
             assigned.

          -  Hemoglobin less than 1000 g/L or platelet count &lt;75×109 U/L or total number of white
             blood cell (WBC) &lt;3×109 U/L.

          -  Prepare to have expected bleeding occurred invasive examination (besides checking
             routine endoscopy) or operation of the subjects during the study period.

          -  Accept any research-based drug or device Within 3 months before randomly assigned, or
             program in such research treatment during the period of research.

          -  Any of the following diagnosis or condition of the subjects:Active malignant tumors
             diagnosed in recent 5 years,except those who get adequate treatment of non melanoma
             skin cancer or other non-invasive or carcinoma in situ such as original seat of
             cervical cancer; Cancer treatment such as drugs, radiation and/or surgical treatment
             in recent 5 years ;With apparent active disease or infection; Life expectancy＜6
             months.

          -  If the treating physician feel that patient is not eligible for clinical reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GuoPing Yang, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GuoPing Yang, professor</last_name>
    <phone>0086 0731 88618326</phone>
    <email>ygp9880@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The People's Hospital of Hunan Province</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianqiang Peng, professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiying Dai, professor</last_name>
      <phone>13787003252</phone>
      <email>daihaiying@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Gong, professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yumin Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaixin Yu, professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanhua university</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanhua university</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaofeng Zeng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Shaoyang</name>
      <address>
        <city>Shaoyang</city>
        <state>Hunan</state>
        <zip>422000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zewei Ouyang, professor</last_name>
      <email>zwycy4137@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Shaoyang</name>
      <address>
        <city>Shaoyang</city>
        <state>Hunan</state>
        <zip>422001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunmei Lv, professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Xiangtan</name>
      <address>
        <city>Xiangtan</city>
        <state>Hunan</state>
        <zip>411100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Huang, professor</last_name>
      <phone>13607327390</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Xiangtan</name>
      <address>
        <city>Xiangtan</city>
        <state>Hunan</state>
        <zip>411101</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanghua Xu, professor</last_name>
      <phone>13657323073</phone>
      <email>xufanghua@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 6, 2016</lastchanged_date>
  <firstreceived_date>August 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AF or DVT</keyword>
  <keyword>Age Over 60 Years, Acquired</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
